Mattioli A V, Masciocco L, Tondi S, Mattioli G
Cardiologia. 1989 Dec;34(12):1021-5.
We performed hemodynamic monitoring in 13 patients, 10 males and 3 females, mean age 57 +/- 11 years, affected by congestive heart failure, NYHA class III and IV. Hemodynamic evaluation was made at basal condition and for 40 min after the administration of nicardipine (10 mg iv). We observed that in 3 patients cardiac index didn't rise (increase less than 15%) with clinical worsening during the monitoring (patients non responders), while in 10 patients cardiac index increased more than 15% (patients responders). Patients responders, 8 males and 2 females, mean age 57 +/- 10 years, have been treated with oral nicardipine administered at the dosage of 40 mg td for 3 months. Three months after nicardipine treatment we observed a significant increase of exercise capacity and O2 uptake (respectively p less than 0.05 and p less than 0.01); we noted also an improvement of cardio-thoracic ratio and of San Diego index (p less than 0.05). We conclude that patients responders to iv nicardipine receive beneficial clinical effects by chronic oral nicardipine.
我们对13例患者进行了血流动力学监测,其中男性10例,女性3例,平均年龄57±11岁,患有充血性心力衰竭,纽约心脏协会(NYHA)心功能分级为III级和IV级。在基础状态下以及静脉注射尼卡地平(10mg)后40分钟进行血流动力学评估。我们观察到,在3例患者中,心脏指数未升高(增加少于15%),且在监测期间临床症状恶化(无反应患者),而在10例患者中,心脏指数增加超过15%(有反应患者)。有反应患者中,男性8例,女性2例,平均年龄57±10岁,接受了口服尼卡地平治疗,剂量为40mg,每日3次,持续3个月。尼卡地平治疗3个月后,我们观察到运动能力和氧摄取量显著增加(分别为p<0.05和p<0.01);我们还注意到心胸比率和圣地亚哥指数有所改善(p<0.05)。我们得出结论,静脉注射尼卡地平有反应的患者通过长期口服尼卡地平可获得有益的临床效果。